Business Context and Reporting Period
This Form 10-Q covers LecTec Corporation (not Axogen, Inc.) for the quarterly and six-month periods ended December 31, 1998. The Company manufactures medical products, including conductive products, medical tapes, and therapeutic patches (TheraPatch). The filing notes the Company is a Minnesota corporation with no securities registered under Section 12(b) of the Exchange Act.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1998 | Six Months Ended Dec 31, 1998 |
|---|---|---|
| Net Sales | $3,103,277 | $6,006,334 |
| Gross Profit | $925,738 (29.8% margin) | $1,942,991 (32.3% margin) |
| Net Loss | $(661,216) | $(813,433) |
| Loss Per Share (Basic/Diluted) | $(0.17) | $(0.21) |
| Cash and Equivalents | $1,022,455 (Ending Balance) | Decreased $1,164,077 from prior period |
| Working Capital | $4,219,466 | Decreased from $5,335,861 |
| Current Ratio | 3.1 | Decreased from 4.8 |
| Debt | $0 | No short or long-term debt outstanding |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.2% in the quarter and 13.5% for the six-month period compared to the prior year. This was driven by a 39.3% drop in medical tape sales (due to intermittent international customer purchases) and a 5.2% drop in conductive product sales.
- Profitability Shift: Despite lower sales, gross profit margins improved (29.8% vs. 28.6% in the quarter) due to a sales mix shift toward higher-margin TheraPatch products sold directly to retailers.
- Operating Expenses Surge: Sales and marketing expenses more than doubled in the quarter (from $244,879 to $545,938) due to the launch of the TheraPatch family. General and administrative expenses increased significantly, including $126,000 related to renegotiating a cotinine license agreement and $42,000 in patent legal fees.
- Cash Flow: Operating activities used $468,717 in cash for the six months, compared to providing $806,569 in the prior year. This was primarily due to the net loss and increased receivables and inventory.
Guidance, Outlook, and Risks
- Outlook: Management anticipates sales and marketing expenses as a percentage of sales will decrease as TheraPatch volume increases. General and administrative expenses are expected to stabilize at approximately 20% of net sales for the remainder of fiscal 1999.
- Liquidity: The Company has no debt and believes existing cash, internal cash flow, and the expected renewal of a $1,000,000 working capital line of credit (expired Sept 1998) will support operations for the next 12-18 months.
- Stock Repurchase: The Company is actively repurchasing shares under a program authorizing up to 500,000 shares. As of Feb 10, 1999, 195,150 shares had been repurchased for $648,900.
- Year 2000 (Y2K) Risk: The Company is approximately 85% complete with internal system testing and 50% complete with third-party risk evaluation. Total estimated compliance costs are under $50,000. Management considers the risk of non-compliance minimal but acknowledges potential disruptions from critical third-party providers (e.g., utilities).
- Contingencies: No material legal proceedings are pending. The Company has a deficit in retained earnings of $2,911,234.
Investor Verification Checklist
- Revenue Sustainability: Verify the stability of international medical tape customers and the success of the direct-to-retailer TheraPatch launch in offsetting legacy product declines.
- Expense Trajectory: Monitor if sales and marketing expenses decrease as a percentage of revenue once the initial product launch costs are absorbed.
- Line of Credit Renewal: Confirm the renewal of the $1,000,000 working capital line of credit, which expired in September 1998, to ensure liquidity coverage.
- Y2K Compliance: Track the completion of Phase IV testing (internal systems) and Phase III (third-party risk) to ensure no operational disruptions occur in early 1999.
- Stock Repurchase Impact: Assess the impact of ongoing share buybacks on cash reserves versus the need for capital to fund the new Consumer Products Division.